expected to prevent an even broader spectrum of HPV-related cancers and other diseases that contribute to 5% of cervical cancer over 100 years. When vaccination of girls with the nonavalent vaccine was extended to boys, the cumulative reduction over 100 years in the incident cases was 498,007 and 39,489 of CIN2/3 and cervical cancer respectively. CONCLUSIONS: The introduction of nonavalent HPV vaccine immunization program in Germany is estimated to significantly reduce the public health impact of cervical and other HPV-related diseases.

PCN186

COST-EFFECTIVENESS AND FEASIBILITY OF IMPLEMENTING MRI-GUIDED NEOADJUVANT CHEMOTHERAPY: METHODOLOGY TO TREAT ER-POSITIVE HER2-NEGATIVE BREAST CANCERS IN THE NETHERLANDS

Miquel-Cases A1, Steuten L2, Rigter L3, van Harten WH4

1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Washington and Harborview Medical Center, Seattle, USA

OBJECTIVES: Evidence suggests that response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive epidermal growth factor receptor 2 positive (ER+/HER2-) breast cancer patients. We estimated the expected cost-effectiveness and resource requirements of implementing RG-NACT with MRI vs. conventional-NACT for treatment of ER+/HER2- breast cancers in the Netherlands (NL). METHODS: A Markov model was developed to analyse the incremental costs and effects from a hospital perspective over a 5-year time horizon. Health services required (MRI scans performed, MRI technologists, breast radiologists and confirmatory scans) for and health outcomes (prevented relapses, prevented deaths, patients with adverse events or contraindications and MRI technologists with adverse events) of implementing RG-NACT were estimated via resource modelling analysis considering the current (9.0%) and a full implementation (100.0%) scenarios in the Dutch population of ER+/HER2+ breast cancer women (n=6306). RESULTS: RG-NACT is expected to generate cost savings of €0.01 and 0.07 QALYs and save €8 and €341 costs for the 4% and 100% implementation scenarios respectively At current implementation rate, 213 MRI examinations, 273 MRI technologists and 1 breast radiologist are required to prevent 0.4 relapses and 6 cancer deaths. At full implementation, a 25-fold increase in MRI examinations is projected, requiring ~5 times higher MRI utilization and ~6500 additional MRI technologists, which is expected to prevent 10 additional relapses (~2400€) and 169 cancer deaths (~€100 000). Decreasing implementation rates markedly increase the number of confirmatory scans (~900), contraindications (~932) and MRI technologists experiencing adverse events (~1706) by 25-fold, and decreased the number of patients with adverse events (~29) by 25-fold. CONCLUSIONS: RG-NACT likely dominates conventional-NACT at current and full implementation rates. Full implementation generates a 25-fold increase in additional health benefits, but requires MRI capacity in the Netherlands to be increased 5-fold, which is challenging given a shortage of MRI technologists.

PCN187

ECONOMIC EVALUATION OF ORAL CHEMOTHERAPY REGIMEN IN METASTATIC BREAST CANCER EGYPTEAN PROSPECTIVE

Abou Taleb AM1, Saida AS A2, Aboushady R3

1WHO, Cairo, Egypt, 2An Naim University, Cairo, Egypt, 3Central Administration for Pharmaceutical Affairs, Cairo, Egypt

OBJECTIVES: The main objective for conducting this study was to evaluate economic evaluation through the cost-effectiveness study of oral chemotherapy regimens we choose vinorelbine oral capsule plus oral capcitabine versus docetaxel 7.5 oral capcitabine in treatment of metastatic breast cancer, in the Egyptian patients previously treated with anthracycline, from the national fund perspective over a time horizon of 6 months. METHODS: A cost-effectiveness analysis from the perspective of the Ministry of Health and Population was conducted. A Markov model was applied with three health states. Utility data were incorporated in the model to make adjusted results. Costs used were the local ones according to the national fund list. Discounting was applied at 3.5% annually both on costs and benefits. The results obtained were in term of ICER and number of QALYS. Robustness of our findings was checked using sensitivity analyses. Results are expressed in QALYS. RESULTS: During the economic impact analysis, the total cost and benefit of treatment with vinorelbine oral plus capcitabine was associated with a 2.46€ gain. The total for docetaxel IV was associated with 0.84 QALY gained. That yields a difference of 1.62 QALYs in favor of oral chemotherapy. Vinorelbine oral plus capcitabine is economically dominating the docetaxel strategy, producing more benefit at a lower cost. The one-dimensional sensitivity analysis indicated that the overall survival medians of both drugs had the largest impact on the results. When conducting sensitivity analysis, both scales ranges. Vinorelbine oral remaining economically dominant in all cases. CONCLUSIONS: The introduction of oral chemotherapy regimens in metastatic breast cancer vinorelbine oral to the national fund Pay-at-The-Expense of-the-State (PFTS) system was likely be cost saving based strictly from its perspective.

PCN188

NONAVALENT VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+ BREAST CANCER PATIENTS: A MACEDONIAN COST-MINIMIZATION ANALYSIS

Nestorovska A1, Naumoska Z1, Grozdanova A1, Stoikoski D2, Ivanovska A2, Risteski M3

1ISPOR Republic of Macedonia regional chapter, Skopje, Macedonia, 2Roche Macedonia, DOOEL, Skopje, Macedonia, 3University Church of Radiotherapy and Oncology, Skopje, Macedonia, "Clinical Hospital Center, "Ss. Cyril and Methodius", Skopje, Macedonia

OBJECTIVES: The aim of this study is to compare the total cost of subcutaneous trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer patients from the R. Macedonia. Recent studies suggest that SC-TRA has a pharmacokinetic profile and efficacy non inferior to standard IV-TRA and is a valid alternative for the treatment of eligible breast cancer patients. METHODS: A cost-minimization analysis was performed using data from prior prospective time-mo study. Total time cost of both types of TRA administration were quantified in a time horizon of over 18 cycles therapy course. The total of 169 patients (mean weight 74.20 kg) (300 observed episodes) from two oncology clinics were enrolled. Patients were HER2+ and received the drug in the aduvant (132 patients) or first line metastatic (57 patients) time horizons in 10% of cases. The choice of trastuzumab regimen was left to the discretion of the treating medical oncologist. Data were obtained from the national health system. RESULTS: Direct medical costs per (mean weight patient) was €30 500 for IV-TRA and €30 102 for SC-TRA. The mean total costs per patient of IV compared to SC, the administration of TRA was a cost saving of €4 404 respectively. SC-TRA incurred less non drug related cost (€4 20) than IV-TRA (€196). The results of the model were most sensitive to patient weight and % of wa tollage, received the drug in patients. Mean cost saving per patient for a full treatment course for SC administration was €589.2. Mean savings (preparation and administration) in time with SC-TRA were 47 min. CONCLUSIONS: SC-TRA can be time and cost-saving therapy for HER2+ breast cancer patients from the R. Macedonia.

PCN189

PHARMACOECONOMIC EVALUATION OF THE USE OF TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION COMPARED TO INTRAVENOUS DOSE FORM IN THE TREATMENT OF BREAST CANCER

Kulakov A, Rybchenko Y

1M. Sechenov First Moscow State Medical University, Moscow, Russia

OBJECTIVES: To determine the preferable treatment scheme for breast cancer (BC) from the pharmacoeconomic perspective by the comparison of subcutaneous (SC) and intravenous (IV) administration. METHODS: The following pharmacoeconomic methods were used: cost-minimization analysis, budget impact analysis. RESULTS: The cost-minimization analysis the following costs were included: cost of testing on tumor expression of HER2, the main drug therapy, concomitant therapy (medical services and drugs), introduction, services provided by medical personnel and the conditions of administration (in case of hospitalization or outpatient). Total costs per 1 patient with BC for treatment course with trastuzumab for subcutaneous administration were 1 314 181 RUB/21 863 EUR and 1 503 716 RUB/25 016 EUR of trastuzumab for IV administration. CONCLUSIONS: The change from trastuzumab for IV administration on trastuzumab for SC administration gave economy of 189 535 RUB/3 153 EUR per 1 patient for treatment course. According to budget impact analysis trastuzumab for SC administration allows to make economy of 177 083 678 RUB/ 2 945 994EUR. The results suggest that trastuzumab for SC administration is more preferable that trastuzumab for IV administration. In time SC-TRA were 47 min. CONCLUSIONS: SC-TRA can be time and cost-saving therapy for HER2+ breast cancer patients from the R. Macedonia.

PCN190

PHARMACOECONOMIC STUDY OF THE USE OF RITUXIMAB FOR SUBCUTANEOUS ADMINISTRATION IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Kulakov A, Rybchenko Y

1M. Sechenov First Moscow State Medical University, Moscow, Russia

OBJECTIVES: To determine the most preferable from the pharmacoeconomic perspective treatment scheme of follicular lymphoma (FL) treatment with rituximab for subcutaneous (SC) and intravenous (IV) administration. METHODS: For this objective, the following pharmacoeconomic methods were used: cost-minimization analysis, budget impact analysis. RESULTS: The following costs were calculated for cost-minimization analysis: the main drug therapy, concomitant therapy, including medical services and medicines, administration, services provided by medical personnel and the conditions of administration (outpatient or hospitalization). According to the cost analysis it was determined that cost of FL treatment was €1 898 803 EUR under IV administration and 3 498 846 RUB/58 207 EUR under SC one. Cost-minimization analysis revealed that rituximab for SC administration compared with IV one gives economy of 35 847 RUB/ 596 EUR per one patient for treatment course. Budget impact analysis showed that rituximab for SC administration allows to make economy of 177 083 678 RUB/ 2 945 994EUR economy for treatment course of all patients in Russia. CONCLUSIONS: According to cost-minimization analysis, subcutaneous administration of rituximab allows to obtain economy compared with intravenous form. Budget impact analysis shows that change of BC treatment from trastuzumab for IV administration on trastuzumab for SC one give monetary economy.